Press Room


    Press Release - August 11, 2003

    Pheromone Successfully Completes Dairy Cow Fertility Monitoring Study

    Toronto, Ontario (August 11, 2003) -- Pheromone Sciences Corp (TSX: PHS), today announced that it has successfully completed its first field trial of its proprietary fertility and ovulation detection technology for large animal breeding at the Ontario Veterinary College under the direction of Dr. Walter H. Johnson DVM, MVSc, Dipl. ACT, and Professor of Theriogenology at the University of Guelph.

    The trial, which used devices designed for human wear comprised enrolling 55 cows as registered subjects with a view to evaluating the sensors ability to detect hormone- related changes indicative of heat. Adequate sensor data as well as complete progesterone and ultrasound records were obtained in 32 of these subjects that reflected a 58% operational trial enrollment completion success rate.

    The trial's endpoint results coupled with the simulation derived from proposed changes to the computer algorithm suggest that the Company's ability to adapt its proprietary Fertilit�©-OVâ�¢ Monitor technology to the specific physiology of the dairy cow in the dairy farm environment, can meet a success level, defined as the correct prediction of oncoming estrus, of 60%. Additional feasibility trials will be undertaken to further study and confirm this anticipated success rate upon implementation of the changes to the computer algorithm. The actual "window of opportunity" for dairy cow breeding would be predictions of ovulation - -2 days to 0 days before ovulation, a recognized requirement for successful breeding.

    "These results compare very favorably to those rates achieved with current technologies available to the small and large scale dairy farmer," commented Dr. Johnson. "We are very pleased that this collaboration with the scientific staff of Pheromone Sciences, continues to build momentum. "A product that can increase conception rates in dairy herd breeding would positively impact productivity on dairy farms across North America", Dr. Johnson added.

    Dairy industry researchers estimate that within the North American dairy industry U.S. producers incur revenue losses directly attributable to inefficient herd reproduction management of approx. US$400 million per annum. The ability to provide accurate monitoring of the fertility status of commercial livestock would afford a significant commercial opportunity for both the agricultural community and Pheromone Sciences Corp.

    "We are enthusiastic about the results from this trial at the Ontario Veterinary College. We were pleased to be able to identify parameters which will help adapt the technology to the farm environment," said Doug Marett, Pheromone Sciences Chief Scientific Officer. "We will now look to optimize the design as part of the process of bringing this product to the commercialization stage in the future.

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.

    Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

    INVESTOR CONTACT Lorne Woods 1-(800) 937-3095


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News